• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

人群简化乳腺癌风险预测模型的验证。

Validation of an Abridged Breast Cancer Risk Prediction Model for the General Population.

机构信息

Phenogen Sciences Inc, Charlotte, North Carolina.

Genetic Technologies Limited, Fitzroy, Victoria, Australia.

出版信息

Cancer Prev Res (Phila). 2023 May 1;16(5):281-291. doi: 10.1158/1940-6207.CAPR-22-0460.

DOI:10.1158/1940-6207.CAPR-22-0460
PMID:36862830
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10150247/
Abstract

In this prospective population-based cohort study, we show the improved performance of a new risk assessment model compared with a gold-standard model (BCRAT). The classification of at-risk women using this new model highlights the opportunity to improve risk stratification and implement existing clinical risk-reduction interventions.

摘要

在这项前瞻性的基于人群的队列研究中，我们展示了一个新的风险评估模型与金标准模型（BCRAT）相比的性能改善。使用这个新模型对高危女性的分类突出了改善风险分层和实施现有临床风险降低干预的机会。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3794/10150247/c4c4a0fe3296/281fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3794/10150247/50a12c660fd4/281fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3794/10150247/c4c4a0fe3296/281fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3794/10150247/50a12c660fd4/281fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3794/10150247/c4c4a0fe3296/281fig2.jpg

相似文献

1
Validation of an Abridged Breast Cancer Risk Prediction Model for the General Population.人群简化乳腺癌风险预测模型的验证。
Cancer Prev Res (Phila). 2023 May 1;16(5):281-291. doi: 10.1158/1940-6207.CAPR-22-0460.
2
10-year performance of four models of breast cancer risk: a validation study.四种乳腺癌风险模型的 10 年表现：一项验证研究。
Lancet Oncol. 2019 Apr;20(4):504-517. doi: 10.1016/S1470-2045(18)30902-1. Epub 2019 Feb 21.
3
Validation of breast cancer risk assessment tools on a French-Canadian population-based cohort.基于法裔加拿大人群队列的乳腺癌风险评估工具验证
BMJ Open. 2021 Apr 12;11(4):e045078. doi: 10.1136/bmjopen-2020-045078.
4
Model for individualized prediction of breast cancer risk after a benign breast biopsy.良性乳腺活检后乳腺癌风险个体化预测模型。
J Clin Oncol. 2015 Mar 10;33(8):923-9. doi: 10.1200/JCO.2014.55.4865. Epub 2015 Jan 26.
5
Breast cancer risk assessment across the risk continuum: genetic and nongenetic risk factors contributing to differential model performance.乳腺癌风险连续体中的风险评估：影响不同模型性能的遗传和非遗传风险因素
Breast Cancer Res. 2012 Nov 5;14(6):R144. doi: 10.1186/bcr3352.
6
Prospective validation of the NCI Breast Cancer Risk Assessment Tool (Gail Model) on 40,000 Australian women.40000 名澳大利亚女性的 NCI 乳腺癌风险评估工具（ Gail 模型）前瞻性验证。
Breast Cancer Res. 2018 Dec 20;20(1):155. doi: 10.1186/s13058-018-1084-x.
7
Development and evaluation of a risk assessment tool for the personalized screening of breast cancer in Chinese populations: A prospective cohort study.中文人群乳腺癌个体化筛查风险评估工具的建立与评价：前瞻性队列研究。
Cancer. 2024 Apr 15;130(S8):1403-1414. doi: 10.1002/cncr.35095. Epub 2023 Nov 2.
8
Incremental impact of breast cancer SNP panel on risk classification in a screening population of white and African American women.乳腺癌 SNP 面板对白人及非裔美国妇女筛查人群风险分类的增量影响。
Breast Cancer Res Treat. 2013 Apr;138(3):889-98. doi: 10.1007/s10549-013-2471-8. Epub 2013 Mar 10.
9
Machine learning techniques for personalized breast cancer risk prediction: comparison with the BCRAT and BOADICEA models.机器学习技术在个体化乳腺癌风险预测中的应用：与 BCRAT 和 BOADICEA 模型的比较。
Breast Cancer Res. 2019 Jun 20;21(1):75. doi: 10.1186/s13058-019-1158-4.
10
Predicting breast cancer risk using personal health data and machine learning models.利用个人健康数据和机器学习模型预测乳腺癌风险。
PLoS One. 2019 Dec 27;14(12):e0226765. doi: 10.1371/journal.pone.0226765. eCollection 2019.

引用本文的文献

1
Development and performance of female breast cancer incidence risk prediction models: a systematic review and meta-analysis.女性乳腺癌发病风险预测模型的开发与性能：一项系统评价和荟萃分析。
Ann Med. 2025 Dec;57(1):2534522. doi: 10.1080/07853890.2025.2534522. Epub 2025 Jul 20.
2
Cancer incidence inconsistency between UK Biobank participants and the population: a prospective cohort study.英国生物银行参与者与总体人群之间癌症发病率的不一致性：一项前瞻性队列研究。
BMC Med. 2025 Mar 26;23(1):181. doi: 10.1186/s12916-025-03998-z.
3
Genomic landscape of cancer in racially and ethnically diverse populations.

本文引用的文献

1
Validation of a breast cancer risk prediction model based on the key risk factors: family history, mammographic density and polygenic risk.基于关键风险因素（家族史、乳腺密度和多基因风险）的乳腺癌风险预测模型的验证。
Breast Cancer Res Treat. 2023 Apr;198(2):335-347. doi: 10.1007/s10549-022-06834-7. Epub 2023 Feb 7.
2
Healthcare professionals' views following implementation of risk stratification into a national breast cancer screening programme.实施风险分层后，医疗保健专业人员对国家乳腺癌筛查计划的看法。
BMC Cancer. 2022 Oct 12;22(1):1058. doi: 10.1186/s12885-022-10134-0.
3
Prospective validation of the BOADICEA multifactorial breast cancer risk prediction model in a large prospective cohort study.
不同种族和族裔人群中癌症的基因组格局。
Nat Rev Genet. 2025 May;26(5):336-349. doi: 10.1038/s41576-024-00796-w. Epub 2024 Nov 28.
4
Breast Cancer Screening and Prophylactic Mastectomy for High-Risk Women in Romania.罗马尼亚高危女性的乳腺癌筛查与预防性乳房切除术
Medicina (Kaunas). 2024 Mar 30;60(4):570. doi: 10.3390/medicina60040570.
5
Assessing the Value of Incorporating a Polygenic Risk Score with Nongenetic Factors for Predicting Breast Cancer Diagnosis in the UK Biobank.评估将多基因风险评分与非遗传因素相结合用于预测英国生物银行中乳腺癌诊断的价值。
Cancer Epidemiol Biomarkers Prev. 2024 Jun 3;33(6):812-820. doi: 10.1158/1055-9965.EPI-23-1432.
前瞻性验证 BOADICEA 多因素乳腺癌风险预测模型在大型前瞻性队列研究中的应用。
J Med Genet. 2022 Dec;59(12):1196-1205. doi: 10.1136/jmg-2022-108806. Epub 2022 Sep 26.
4
Breast cancer risk stratification in women of screening age: Incremental effects of adding mammographic density, polygenic risk, and a gene panel.筛查年龄段女性的乳腺癌风险分层：加入乳腺密度、多基因风险和基因panel 的增量效应。
Genet Med. 2022 Jul;24(7):1485-1494. doi: 10.1016/j.gim.2022.03.009. Epub 2022 Apr 15.
5
Prospective evaluation of a breast-cancer risk model integrating classical risk factors and polygenic risk in 15 cohorts from six countries.前瞻性评估一个乳腺癌风险模型，该模型整合了来自六个国家的 15 个队列中的经典风险因素和多基因风险。
Int J Epidemiol. 2022 Jan 6;50(6):1897-1911. doi: 10.1093/ije/dyab036. Epub 2021 Mar 23.
6
Elevated risk thresholds predict endocrine risk-reducing medication use in the Athena screening registry.在雅典娜筛查登记处，较高的风险阈值预示着内分泌风险降低药物的使用。
NPJ Breast Cancer. 2021 Aug 3;7(1):102. doi: 10.1038/s41523-021-00306-9.
7
Performance of the IBIS/Tyrer-Cuzick model of breast cancer risk by race and ethnicity in the Women's Health Initiative.IBIS/Tyrer-Cuzick 乳腺癌风险模型在妇女健康倡议中的种族和民族表现。
Cancer. 2021 Oct 15;127(20):3742-3750. doi: 10.1002/cncr.33767. Epub 2021 Jul 6.
8
Development and pilot of an online, personalized risk assessment tool for a breast cancer precision medicine trial.用于乳腺癌精准医学试验的在线个性化风险评估工具的开发与试点
NPJ Breast Cancer. 2021 Jun 17;7(1):78. doi: 10.1038/s41523-021-00288-8.
9
Comparison of the Prevalence of Pathogenic Variants in Cancer Susceptibility Genes in Black Women and Non-Hispanic White Women With Breast Cancer in the United States.美国乳腺癌黑种女性与非西班牙裔白种女性中癌症易感性基因致病性变异患病率比较。
JAMA Oncol. 2021 Jul 1;7(7):1045-1050. doi: 10.1001/jamaoncol.2021.1492.
10
Comparative validation of the BOADICEA and Tyrer-Cuzick breast cancer risk models incorporating classical risk factors and polygenic risk in a population-based prospective cohort of women of European ancestry.基于欧洲血统女性的人群前瞻性队列中，纳入经典风险因素和多基因风险的 BOADICEA 和 Tyrer-Cuzick 乳腺癌风险模型的比较验证。
Breast Cancer Res. 2021 Feb 15;23(1):22. doi: 10.1186/s13058-021-01399-7.